REFINITIV

DELTA REPORT

10-Q

NARI - INARI MEDICAL, INC.

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1044
CHANGES	218
DELETIONS	373
ADDITIONS	453

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2023 March 31, 2024

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ___________to ___________

Commission File Number: 001-39293

InariMedical_Logo_R small.jpg

Inari Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	**45-2902923**
(State or other jurisdiction of incorporation or organization)	**(I.R.S. Employer Identification No.)**
6001 Oak Canyon, Suite 100 Irvine, California	**92618**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (877) 923-4747

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.001 par value per share	NARI	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 27, 2023 April 26, 2024, the registrant had 57,590,463 58,138,159 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. We intend the such forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of

1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "would," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "may", "will", "would", "should", "expects", "plans", "anticipates", "could", "intends", "targets", "projects", "contemplates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, without limitation, but are not limited to statements regarding our business model future results of operations and strategic financial position, plans for our products, anticipated closing of the expectations regarding our recent acquisition of LimFlow S.A., technologies and business, including our implementation thereof, the impact of macroeconomic conditions, on our business, financial condition and results of operations, industry and business trends, and our expectations regarding stock compensation, business strategy, plans, market growth, regulatory climate, competitive landscape and our objectives for future operations.

The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations. Forward-looking statements involve known and unknown risks and uncertainties, and are subject to other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, as such risks and uncertainties may be amended, supplemented or superseded from time to time by our subsequent reports on Forms 10-Q and 10-K we file with the United States Securities and Exchange Commission. We qualify all of our forward-looking statements by these cautionary statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

PART I — FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value)
(unaudited)

	September 30, 2023	December 31, 2022

	March 31, 2024			March 31, 2024	December 31, 2023
Assets	**Assets**				
Current assets	**Current assets**				
Current assets					
Current assets					
Cash and cash equivalents	Cash and cash equivalents	$ 89,182	$ 60,222		
Cash and cash equivalents					
Cash and cash equivalents					
Restricted cash					
Short-term investments in debt securities	Short-term investments in debt securities	262,113	266,179		
Accounts receivable, net	Accounts receivable, net	69,595	58,611		
Inventories, net	Inventories, net	40,227	32,581		
Prepaid expenses and other current assets	Prepaid expenses and other current assets	7,944	5,312		
Total current assets	Total current assets	469,061	422,905		
Property and equipment, net	Property and equipment, net	21,243	21,655		
Operating lease right-of-use assets	Operating lease right-of-use assets	49,065	50,703		
Goodwill					
Intangible assets					
Deposits and other assets	Deposits and other assets	9,466	8,889		
Total assets	**Total assets**	$548,835	$504,152		
Total assets					
Total assets					

Liabilities and Stockholders' Equity	**Liabilities and Stockholders' Equity**		
Current liabilities	**Current liabilities**		
Current liabilities			
Current liabilities			
Accounts payable			
Accounts payable			
Accounts payable	Accounts payable	$ 10,091	$ 7,659
Payroll-related accruals	Payroll-related accruals	41,305	38,955
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	13,040	8,249
Operating lease liabilities, current portion	Operating lease liabilities, current portion	1,630	1,311
Total current liabilities	Total current liabilities	66,066	56,174
Operating lease liabilities, noncurrent portion	Operating lease liabilities, noncurrent portion	30,627	30,976
Deferred tax liability			
Other long-term liability			
Total liabilities	**Total liabilities**	96,693	87,150
Commitments and contingencies (Note 7)			
Commitments and contingencies (Note 9)	**Commitments and contingencies (Note 9)**		
Stockholders' equity	**Stockholders' equity**		

Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and December 31, 2022	—	—
Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 57,506,462 and 54,021,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	58	54
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023		
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023		
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023		

Common stock, $0.001 par value, 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 58,001,145 and 57,762,414 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively			
Additional paid in capital	Additional paid in capital	497,063	462,949
Accumulated other comprehensive (loss) income		(1,158)	849
Accumulated other comprehensive income			
Accumulated deficit	Accumulated deficit	(43,821)	(46,850)
Total stockholders' equity	**Total stockholders' equity**	452,142	417,002
Total liabilities and stockholders' equity	**Total liabilities and stockholders' equity**	$548,835	$504,152

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)

	Three Months Ended September 30,	Nine Months Ended September 30,

		2023	2022	2023	2022
		Three Months Ended March 31,			
		Three Months Ended March 31,			
		Three Months Ended March 31,			
		2024			
		2024			
		2024			
Revenue					
Revenue					
Revenue	Revenue	$ 126,366	$ 96,204	$ 361,538	$ 275,700
Cost of goods sold	Cost of goods sold	14,477	11,064	42,062	31,378
Cost of goods sold					
Cost of goods sold					
Gross profit					
Gross profit					
Gross profit	Gross profit	111,889	85,140	319,476	244,322
Operating expenses	Operating expenses				
Operating expenses					
Operating expenses					
Research and development					
Research and development					
Research and development	Research and development	21,492	19,105	64,641	53,809
Selling, general and administrative	Selling, general and administrative	88,284	75,833	259,570	212,721
Selling, general and administrative					
Selling, general and administrative					
Change in fair value of contingent consideration					
Change in fair value of contingent consideration					
Change in fair value of contingent consideration					
Amortization of intangible asset					
Amortization of intangible asset					
Amortization of intangible asset					
Acquisition-related expenses					
Acquisition-related expenses					
Acquisition-related expenses					
Total operating expenses	Total operating expenses	109,776	94,938	324,211	266,530
Income (loss) from operations		2,113	(9,798)	(4,735)	(22,208)

Total operating expenses					
Total operating expenses					
Loss from operations					
Loss from operations					
Loss from operations					
Other income (expense)					
Other income (expense)					
Other income (expense)	Other income (expense)				
Interest income	Interest income	4,202	618	12,899	882
Interest income					
Interest income					
Interest expense					
Interest expense					
Interest expense	Interest expense	(43)	(74)	(127)	(220)
Other (expense) income	Other (expense) income	(682)	(59)	(617)	169
Other (expense) income					
Other (expense) income					
Total other income	Total other income	3,477	485	12,155	831
Income (loss) before income taxes		5,590	(9,313)	7,420	(21,377)
Total other income					
Total other income					
Loss before income taxes					
Loss before income taxes					
Loss before income taxes					
Provision for income taxes	Provision for income taxes	2,428	840	4,391	2,092
Net income (loss)		$ 3,162	$ (10,153)	$ 3,029	$ (23,469)
Provision for income taxes					
Provision for income taxes					
Net loss					
Net loss					
Net loss					
Other comprehensive income (loss)					
Other comprehensive income (loss)					
Other comprehensive income (loss)	Other comprehensive income (loss)				
Foreign currency translation adjustments	Foreign currency translation adjustments	(68)	(406)	(138)	(814)
Unrealized gain (loss) on available-for-sale debt securities		91	644	(1,869)	271

Total other comprehensive income (loss)			23		238		(2,007)		(543)
Comprehensive income (loss)		$	3,185	$	(9,915)	$	1,022	$	(24,012)
Net income (loss) per share									
Foreign currency translation adjustments									
Foreign currency translation adjustments									
Unrealized loss on available-for-sale debt securities									
Unrealized loss on available-for-sale debt securities									
Unrealized loss on available-for-sale debt securities									
Total other comprehensive loss									
Total other comprehensive loss									
Total other comprehensive loss									
Comprehensive loss									
Comprehensive loss									
Comprehensive loss									
Net loss per share									
Net loss per share									
Net loss per share									
Basic									
Basic									
Basic	Basic	$	0.06	$	(0.19)	$	0.05	$	(0.45)
Diluted	Diluted	$	0.05	$	(0.19)	$	0.05	$	(0.45)
Weighted average common shares used to compute net income (loss) per share									
Diluted									
Diluted									
Weighted average common shares used to compute net loss per share									
Weighted average common shares used to compute net loss per share									
Weighted average common shares used to compute net loss per share									
Basic									
Basic									
Basic	Basic		57,384,884		53,491,625		56,478,317		52,552,662
Diluted	Diluted		58,588,452		53,491,625		58,495,921		52,552,662
Diluted									
Diluted									

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INARI MEDICAL, INC.
Condensed Consolidated Statements Stockholders' Equity
(in thousands, except share data)
(unaudited)

	Common Stock Shares	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2023						
Balance, December 31, 2023						
Balance, December 31, 2023						
Options exercised for common stock						
Shares issued under Employee Stock Purchase Plan						
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes						
Share-based compensation expense						
Other comprehensive loss						
Net loss						
Balance, March 31, 2024						

	Common Stock Shares	Common Stock Amount	Additional Paid In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2022	**54,021,656**	**$ 54**	**$ 462,949**	**$ 849**	**$ (46,850)**	**$ 417,002**
Options exercised for common stock	209,966	—	226	—	—	226

stock						
Shares issued under Employee Stock Purchase Plan	86,051	—	4,172	—	—	4,172
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	2,766,043	3	(1,932)	—	—	(1,929)
Share-based compensation expense	—	—	10,339	—	—	10,339
Other comprehensive loss	—	—	—	(856)	—	(856)
Net loss	—	—	—	—	(2,218)	(2,218)
Balance, March 31, 2023	**57,083,716**	**57**	**475,754**	**(7)**	**(49,068)**	**426,736**
Options exercised for common stock	81,712	—	214	—	—	214
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	101,027	—	(2,569)	—	—	(2,569)
Share-based compensation expense	—	—	10,353	—	—	10,353
Other comprehensive loss	—	—	—	(1,174)	—	(1,174)
Net income	—	—	—	—	2,085	2,085
Balance, June 30, 2023	**57,266,455**	**57**	**483,752**	**(1,181)**	**(46,983)**	**435,645**
Options exercised for common stock	43,547	—	107	—	—	107

Shares issued under Employee Stock Purchase Plan	118,494	1	5,748	—	—	5,749
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	77,966	—	(2,388)	—	—	(2,388)
Share-based compensation expense	—	—	9,844	—	—	9,844
Other comprehensive income	—	—	—	23	—	23
Net income	—	—	—	—	3,162	3,162
Balance, September 30, 2023	**57,506,462**	**$ 58**	**$ 497,063**	**$ (1,158)**	**$ (43,821)**	**$ 452,142**

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INARI MEDICAL, INC.
Condensed Consolidated Statements Stockholders’ Equity
(in thousands, except share data)
(unaudited)

	Common Stock					
	Shares	**Common Stock**	**Additional Paid In Capital**	**Accumulated Other Comprehensive Income (Loss)**	**Accumulated Deficit**	**Total Stockholders' Equity**
Balance, December 31, 2022						
Balance, December 31, 2022						
Balance, December 31, 2022						
Options exercised for common stock						

Shares issued under Employee Stock Purchase Plan
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
Share-based compensation expense
Share-based compensation expense
Share-based compensation expense
Other comprehensive loss
Net loss
Balance, March 31, 2023

	Common Stock		**Additional**	**Accumulated Other**		
	Shares	**Amount**	**Paid In Capital**	**Comprehensive Income (Loss)**	**Accumulated Deficit**	**Total Stockholders' Equity**
Balance, December 31, 2021	**50,313,452**	**$ 50**	**$ 257,144**	**$ (402)**	**$ (17,583)**	**$ 239,209**
Options exercised for common stock	322,882	1	344	—	—	345
Shares issued under Employee Stock Purchase Plan	54,808	—	3,427	—	—	3,427
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	31,763	—	(1,624)	—	—	(1,624)

Issuance of common stock in public offering, net of issuance costs of $11.9 million	2,300,000	2	174,392			174,394
Share-based compensation expense	—	—	6,555	—	—	6,555
Other comprehensive loss	—	—	—	(365)	—	(365)
Net loss	—	—	—	—	(3,129)	(3,129)
Balance, March 31, 2022	**53,022,905**	**53**	**440,238**	**(767)**	**(20,712)**	**418,812**
Options exercised for common stock	228,313	—	156	—	—	156
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	54,607	—	(1,751)	—	—	(1,751)
Share-based compensation expense	—	—	7,164	—	—	7,164
Other comprehensive loss	—	—	—	(416)	—	(416)
Net loss	—	—	—	—	(10,187)	(10,187)
Balance, June 30, 2022	**53,305,825**	**53**	**445,807**	**(1,183)**	**(30,899)**	**413,778**
Options exercised for common stock	167,102	—	109	—	—	109
Shares issued under Employee Stock Purchase Plan	78,707	—	4,995	—	—	4,995

Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes	43,643	—	(1,224)	—	—	(1,224)
Share-based compensation expense	—	—	7,356	—	—	7,356
Other comprehensive income	—	—	—	238	—	238
Net loss	—	—	—	—	(10,153)	(10,153)
Balance, September 30, 2022	**53,595,277**	**$ 53**	**$ 457,043**	**$ (945)**	**$ (41,052)**	**$ 415,099**

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INARI MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

		Nine Months Ended September 30,			
		2023	**2022**		
	Three Months Ended March 31,			**Three Months Ended March 31,**	
	2024			**2024**	**2023**
Cash flows from operating activities	**Cash flows from operating activities**				
Net income (loss)		$ 3,029	$(23,469)		
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:					
Depreciation		4,186	3,430		
Net loss					
Net loss					
Net loss					

Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization		
Depreciation and amortization		
Depreciation and amortization		
Amortization of deferred financing costs		
Amortization of deferred financing costs	30	108
Amortization of right-of-use assets		
Amortization of right-of-use assets	3,099	1,799
Share-based compensation expense		
Share-based compensation expense	30,536	21,075
Impairment loss on strategic investment	565	—
Share-based compensation expense		
Share-based compensation expense		
Allowance for credit losses, net		
Allowance for credit losses, net		
Allowance for credit losses, net		
Allowance for credit losses, net	526	341
Loss on disposal of fixed assets		
Loss on disposal of fixed assets	26	23
Amortization of premium and discount on marketable securities		
Amortization of premium and discount on marketable securities	(11,407)	—
Change in fair value of contingent consideration liability		
Changes in:		
Changes in:		
Changes in:		
Changes in:		
Accounts receivable		
Accounts receivable		

Accounts receivable	Accounts receivable	(11,566)	(12,220)
Inventories	Inventories	(7,797)	(8,706)
Prepaid expenses, deposits and other assets	Prepaid expenses, deposits and other assets	4,294	(1,537)
Accounts payable	Accounts payable	2,436	(441)
Payroll-related accruals, accrued expenses and other liabilities	Payroll-related accruals, accrued expenses and other liabilities	7,218	(562)
Operating lease liabilities	Operating lease liabilities	(1,031)	(565)
Lease prepayments for lessor's owned leasehold improvements	Lease prepayments for lessor's owned leasehold improvements	(458)	(4,503)
Net cash provided by (used in) operating activities		23,686	(25,227)
Net cash used in operating activities			
Cash flows from investing activities	**Cash flows from investing activities**		
Purchases of property and equipment			
Purchases of property and equipment			
Purchases of property and equipment	Purchases of property and equipment	(3,801)	(8,173)
Purchases of marketable securities	Purchases of marketable securities	(394,496)	(332,103)
Maturities of marketable securities	Maturities of marketable securities	400,560	184,000
Purchases of other investments	Purchases of other investments	(565)	(5,693)
Capitalized software development costs			

Capitalized software development costs			
Capitalized software development costs			
Net cash provided by (used in) investing activities	Net cash provided by (used in) investing activities	1,698	(161,969)
Cash flows from financing activities	**Cash flows from financing activities**		
Proceeds from issuance of common stock in public offering, net of issuance costs of $11.9 million		—	174,394
Proceeds from issuance of common stock under employee stock purchase plan			
Proceeds from issuance of common stock under employee stock purchase plan			
Proceeds from issuance of common stock under employee stock purchase plan	Proceeds from issuance of common stock under employee stock purchase plan	9,920	8,422
Proceeds from exercise of stock options	Proceeds from exercise of stock options	547	610
Payment of taxes related to vested restricted stock units		(6,886)	(4,599)
Payment of taxes related to vested equity awards			
Net cash provided by financing activities	Net cash provided by financing activities	3,581	178,827
Effect of foreign exchange rate changes on cash and cash equivalents		(5)	(855)
Net increase (decrease) in cash and cash equivalents		28,960	(9,224)
Cash and cash equivalents beginning of period		60,222	92,752
Cash and cash equivalents end of period		$ 89,182	$ 83,528

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	
Net increase (decrease) in cash, cash equivalents and restricted cash	
Cash, cash equivalents and restricted cash beginning of period	
Cash, cash equivalents and restricted cash end of period	

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

1. ORGANIZATION

Description of Business

Inari Medical, Inc. (the "Company") was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company purpose builds and markets a variety of medical products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems for the unique characteristics of specific disease states.

On November 15, 2023, the Company acquired LimFlow S.A. ("LimFlow"), a medical device company focused in limb salvage for patients with chronic limb-threatening ischemia (CLTI). LimFlow focuses on transforming the treatment of CLTI, an advanced stage of peripheral artery disease that is associated with increased mortality, risk of amputation and impaired quality of life.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The interim condensed consolidated balance sheet as of September 30, 2023 March 31, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders' equity, and cash flows for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 are unaudited. The consolidated balance sheet as of December 31, 2022 December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company's condensed consolidated financial position as of September 30, 2023 March 31, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2023 March 31, 2024 and 2022. 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 31, 2023.

Management Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use ("ROU") assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company sells its products primarily to hospitals in the United States through its direct sales force. force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company's sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand- delivery. hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.

Performance Obligation—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company's products. The satisfaction of this performance obligation occurs with the transfer of control of the Company's product to its customers, either upon shipment or delivery of the product.

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company's condensed consolidated financial statements.

As of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, the Company recorded $1,324,000 $1.0 million and $1,218,000, $1.2 million, respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.

The Company disaggregates revenue by product. Revenue for between Venous Thromboembolism ("VTE") and Emerging Therapies. VTE comprises revenue from the sale of the Company's ClotTriever and other systems FlowTriever systems. Emerging Therapies comprises revenues from the sale of the Company's solutions addressing chronic venous disease, CLTI, small vessel thrombosis and FlowTriever system as a percentage of total revenue arterial thromboembolism. Revenue from VTE and Emerging Therapies is as follows: follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
ClotTriever and other systems	32 %	31 %	34 %	32 %
FlowTriever system	68 %	69 %	66 %	68 %

	Three Months Ended March 31,			
	2024		2023	
VTE	$	137,193	$	114,058
Emerging Therapies		6,001		2,109
Total Revenue	$	143,194	$	116,167

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	2024			
	2024			
	2024			
United States				
United States				

United States	United States	$ 119,825	$ 93,597	$ 345,473	$ 269,584
International	International	6,541	2,607	16,065	6,116
International					
International					
Total revenue	Total revenue	$ 126,366	$ 96,204	$ 361,538	$ 275,700
Total revenue					
Total revenue					

The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.

The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company's warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. The warranty expense recognized was $57,000 and $165,000 during the three months ended

September 30, 2023 and 2022, respectively, and $411,000 and $374,000 for the nine months ended September 30, 2023 and 2022, respectively.

Costs associated with product sales include commissions and are recorded in selling, general and administrative ("SG&A") expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.

Equity Investments

The Company has strategic investments in certain privately-held privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment. investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values. values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the Statements consolidated statements of Operations operations and Comprehensive Income. comprehensive income (loss). As of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, the Company's equity investments were $8.3 million $1.5 million and were included in deposits and other assets on the condensed consolidated balance sheets. Additionally, during the three and nine months ended September 30, 2023, the Company recorded an impairment loss of $0.6 million in other income (expense) in the Statement of Operations and Comprehensive Income. There was no impairment loss recorded during the three and nine months ended September 30, 2022 March 31, 2024 and 2023.

Significant Accounting Policies

As of March 31, 2024, there were no changes to the Company's significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Recently Issued Not Yet Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the CODM. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.

In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.

Supplemental Cash Flow Information

Supplemental cash flow information includes the following: following (in thousands):

		Nine Months Ended September 30,		Three Months Ended March 31,	Three Months Ended March 31,	
		2023	2022	2024	2024	2023
Supplemental disclosures of cash flow information:	**Supplemental disclosures of cash flow information:**					
Cash paid for income taxes						
Cash paid for income taxes						
Cash paid for income taxes	Cash paid for income taxes	$3,562	$3,085			
Cash paid for interest	Cash paid for interest	$ 98	$ 112			
Noncash investing and financing:	**Noncash investing and financing:**					
Noncash investing and financing:						
Noncash investing and financing:						

Lease liabilities arising from obtaining new right-of-use assets	Lease liabilities arising from obtaining new right-of-use assets	$1,030	$2,334

Lease liabilities arising from obtaining new right-of-use assets

Lease liabilities arising from obtaining new right-of-use assets

Reconciliation of cash, cash equivalents and restricted cash:

Reconciliation of cash, cash equivalents and restricted cash:

Reconciliation of cash, cash equivalents and restricted cash:

Cash and cash equivalents

Cash and cash equivalents

Cash and cash equivalents

Restricted cash

Total cash, cash equivalents and restricted cash as shown in the statement of cash flows

3. BUSINESS COMBINATION

Acquisition of LimFlow S.A.

On November 15, 2023, the Company completed its acquisition of LimFlow, a medical device company focused on limb salvage for patients with CLTI. As a result of the acquisition, LimFlow's stockholders received as consideration (i) cash, and (ii) contingent consideration related to certain commercial and reimbursement milestones. The results of operations of LimFlow have been included in the condensed consolidated financial statements from the date of the acquisition.

Purchase Price

The total purchase price as of the date of the acquisition consisted of the following (in thousands):

		As of November 15, 2023
Cash	$	242,001
Fair value of previously held investment		10,235
Fair value of contingent consideration		65,931
Total purchase price	$	318,167

Contingent Consideration

The LimFlow stockholders can achieve up to $165.0 million of additional contingent consideration if certain commercial and reimbursement milestones are achieved, as outlined under the Contingent Payments section of the share purchase agreement with LimFlow. Such payments include (i) up to $140.0 million based on net revenue generated from the sale of the LimFlow System for the year 2024 through 2026 and (ii) up to $25.0 million based on the achievement of certain reimbursement milestones related to the LimFlow System.

The acquisition-date fair value of the contingent consideration was measured using a Monte Carlo simulation which represents Level 3 measurements because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. Estimates and assumptions used in the fair value assessment included forecasted revenues for LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, counterparty credit spread, and weighted average cost of capital. The Company has determined that the range of the potential payments on such contingencies is $65.9 million to $165.0 million. The fair value of the contingent consideration was $65.9 million as of the acquisition date.

Previously Held Investment

Prior to the acquisition, the Company held an investment in LimFlow, which represented approximately 3.7% of LimFlow's outstanding equity, and was recorded at cost minus impairment. Authoritative guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity investment in the acquiree at its acquisition-date fair value and recognize the resulting gain or loss in earnings. In connection with acquiring the remaining 96.3% equity interest of LimFlow, the Company remeasured its previously held equity investment to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred. Estimates and assumptions used in the remeasurement represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring the fair value. As a result of the remeasurement, the Company valued its previously held equity investment in LimFlow at $10.2 million and recognized a gain of $3.5 million, included in other income (expense) in the consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023.

Transaction Costs

The transaction costs associated with the acquisition of LimFlow consisted primarily of legal and financial advisory fees of approximately $8.7 million in addition to $1.7 million of severance and integration related costs, which were expensed as incurred as SG&A expense during the year ended December 31, 2023.

Net Assets Acquired and Liabilities Assumed

The preliminary fair values of assets acquired and liabilities assumed were (in thousands):

		As of November 15, 2023
Cash and cash equivalents	$	1,582
Accounts receivable		919
Inventories		2,635
Property and equipment		266
Goodwill		207,800
Intangible asset		146,000
Other current and noncurrent assets		2,155
Accounts payable		(2,509)
Deferred tax liability		(36,500)
Other current and noncurrent liabilities		(4,181)
Total net assets acquired	$	318,167

The Company is in the process of finalizing the allocation of the purchase price. As a result, the fair value estimates assigned to intangible asset, goodwill and the related tax impacts of the acquisition, among other items, are subject to change as additional information is received to complete the analysis, including final adjustments to net working capital. The Company expects to finalize the valuation as soon as practicable, but no later than one year after the acquisition date.

The preliminary fair value assigned to the intangible asset acquired was as following (in thousands, except for estimated useful life which is in years):

		Fair value	Useful life
Developed technology	$	146,000	15 years

The preliminary fair value assigned to identifiable intangible asset, the developed technology, acquired as part of the LimFlow acquisition, was estimated using the multi-period excess earnings method. Under this method, an intangible asset's fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return. Such assumptions included forecasted revenues, cost of sales and operating expenses, technology obsolescence, and weighted average cost of capital. The useful life of the developed technology for amortization purposes was determined by considering the period of expected cash flows used to measure the fair values of the intangible asset adjusted as appropriate for entity-specific factors including competitive, economic and other factors that may limit the useful life. The developed technology asset will be amortized on a straight-line basis over its estimated useful life.

Unaudited Pro Forma Financial Information

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of the fiscal year 2023 (in thousands):

		Three Months Ended March 31,
		2023
Revenue	$	116,646
Net Loss	$	(13,730)

The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the acquisition been completed at the beginning of the fiscal year 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. The unaudited pro forma financial information includes adjustments to reflect the elimination of intercompany transactions, incremental amortization of the identifiable intangible asset and elimination of the remeasurement the Company’s previously held investment in LimFlow.

4. FAIR VALUE MEASUREMENTS

Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. As of September 30, 2023 March 31, 2024, all of the Company's investments in debt securities had maturities of less than 12 months and were classified as short-term investments on the condensed consolidated balance sheets.

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023 (in thousands):

		September 30, 2023			
		Level 1	Level 2	Level 3	Aggregate Fair Value
	March 31, 2024				
	Level 1				
		March 31, 2024			
		Level 1	Level 2	Level 3	Aggregate Fair Value
Financial Assets	**Financial Assets**				
Cash and cash equivalents:	**Cash and cash equivalents:**				
Cash and cash equivalents:					
Cash and cash equivalents:					
Money market mutual funds	Money market mutual funds	$ 41,561	$ —	$—	$ 41,561
Money market mutual funds					
Money market mutual funds					
U.S. Treasury securities					

		Level 1	Level 2	Level 3	Aggregate Fair Value
Corporate debt securities and commercial paper		—	3,489	—	3,489
Total included in cash and cash equivalents					
Total included in cash and cash equivalents					
Total included in cash and cash equivalents	Total included in cash and cash equivalents	41,561	3,489	—	45,050
Investments:	**Investments:**				
U.S. Treasury securities	U.S. Treasury securities	173,687	—	—	173,687
U.S. Government agencies		—	46,284	—	46,284
U.S. Treasury securities					
U.S. Treasury securities					
Corporate debt securities and commercial paper					
Corporate debt securities and commercial paper					
Corporate debt securities and commercial paper	Corporate debt securities and commercial paper	—	42,142	—	42,142
Total included in short-term investments	Total included in short-term investments	173,687	88,426	—	262,113
Total financial assets	Total financial assets	$215,248	$91,915	$—	$307,163
Financial Liability					
Contingent consideration					
Contingent consideration					
Contingent consideration					
Total financial liabilities					

	December 31, 2022			
	Level 1	Level 2	Level 3	Aggregate Fair Value

		December 31, 2023			December 31, 2023
		Level 1	Level 2	Level 3	Aggregate Fair Value
Financial Assets	**Financial Assets**				
Cash and cash equivalents:	**Cash and cash equivalents:**				
Cash and cash equivalents:					
Cash and cash equivalents:					
Money market mutual funds	Money market mutual funds	$ 20,329	$ —	$—	$ 20,329
Money market mutual funds					
Money market mutual funds					
Total included in cash and cash equivalents					
Total included in cash and cash equivalents					
Total included in cash and cash equivalents	Total included in cash and cash equivalents	20,329	—	—	20,329
Investments:	**Investments:**				
U.S. Treasury securities					
U.S. Treasury securities					
U.S. Treasury securities	U.S. Treasury securities	172,088	—	—	172,088
U.S. Government agencies	U.S. Government agencies	—	47,131	—	47,131
Corporate debt securities and commercial paper	Corporate debt securities and commercial paper	—	46,960	—	46,960
Total included in short-term investments	Total included in short-term investments	172,088	94,091	—	266,179
Total financial assets	Total financial assets	$192,417	$94,091	$—	$286,508

Financial Liability
Contingent consideration
Contingent consideration
Contingent consideration
Total financial liabilities

There were no transfers between Levels 1, 2 or 3 for the periods presented.

Contingent payments are related to the acquisition of LimFlow and consist of commercial and reimbursement milestones, which were valued using a Monte Carlo simulation and probability weighted discounted cash flow analysis, respectively, and represent Level 3 measurements because they are based upon significant unobservable inputs such as forecasted revenues of LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, credit risk, weighted average cost of capital, and probability assumptions in achieving certain milestones.

4. The following table summarizes the changes in the estimated fair value of the Company's contingent consideration liabilities (in thousands):

	Contingent Consideration Fair Value
Balance as of December 31, 2023	$ 65,931
Change in estimated fair value	6,303
Balance as of March 31, 2024	$ 72,234

The fair value of the contingent consideration was $65.9 million as of December 31, 2023, recorded within other long-term liabilities, and $72.2 million as of March 31, 2024, of which $9.3 million was recorded within accrued expenses and other current liabilities and $62.9 million was recorded within other long-term liabilities. The change in estimated fair value of contingent consideration was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss).

5. CASH EQUIVALENTS AND INVESTMENTS

The following is a summary of the Company's cash equivalents and investments in debt securities as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023 (in thousands):

	September 30, 2023			
	Amortized Cost Basis	Unrealized Gain	Unrealized Loss	Fair Value
Financial Assets				

	March 31, 2024	March 31, 2024			
	Amortized Cost Basis	Amortized Cost Basis	Unrealized Gain	Unrealized Loss	Fair Value
Financial Assets					

Cash and cash equivalents:	**Cash and cash equivalents:**				
Cash and cash equivalents:					
Cash and cash equivalents:					
Money market mutual funds	Money market mutual funds	$ 41,561	$ —	$ —	$ 41,561
Corporate debt securities and commercial paper		3,490	—	(1)	3,489
Money market mutual funds					
Money market mutual funds					
U.S. Treasury securities					
Total included in cash and cash equivalents	Total included in cash and cash equivalents	45,051	—	(1)	45,050
Investments:	**Investments:**				
U.S. Treasury securities	U.S. Treasury securities	173,690	9	(12)	173,687
U.S. Government agencies		46,309	7	(32)	46,284
U.S. Treasury securities					
U.S. Treasury securities					
Corporate debt securities and commercial paper					
Corporate debt securities and commercial paper					
Corporate debt securities and commercial paper	Corporate debt securities and commercial paper	42,162	—	(20)	42,142
Total included in short-term investments	Total included in short-term investments	262,161	16	(64)	262,113
Total financial assets	Total financial assets	$307,212	$ 16	$ (65)	$307,163
			December 31, 2022		

		Amortized Cost Basis	Unrealized Gain	Unrealized Loss	Fair Value
	December 31, 2023				
	Amortized Cost Basis				
Financial Assets	**Financial Assets**				
Cash and cash equivalents:	**Cash and cash equivalents:**				
Cash and cash equivalents:					
Cash and cash equivalents:					
Money market mutual funds	Money market mutual funds	$ 20,329	$ —	$ —	$ 20,329
Money market mutual funds					
Money market mutual funds					
Total included in cash and cash equivalents					
Total included in cash and cash equivalents					
Total included in cash and cash equivalents	Total included in cash and cash equivalents	20,329	—	—	20,329
Investments:	**Investments:**				
U.S. Treasury securities					
U.S. Treasury securities					
U.S. Treasury securities	U.S. Treasury securities	171,006	1,120	(38)	172,088
U.S. Government agencies	U.S. Government agencies	46,777	354	—	47,131
Corporate debt securities and commercial paper	Corporate debt securities and commercial paper	46,576	397	(13)	46,960
Total included in short-term investments	Total included in short-term investments	264,359	1,871	(51)	266,179

December 31, 2023			
Amortized Cost Basis	Unrealized Gain	Unrealized Loss	Fair Value

Total financial assets	Total financial assets	$284,688	$ 1,871	$ (51)	$286,508

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

The Company regularly reviews any changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of September 30, 2023 March 31, 2024, the risk of expected credit losses was not significant.

5. 6. INVENTORIES, NET

Inventories, net of reserves, consist of the following (in thousands):

		September 30, 2023	December 31, 2022	
March 31, 2024		March 31, 2024		December 31, 2023
Raw materials	Raw materials	$14,278	$13,943	
Work-in-process	Work-in-process	4,117	3,396	
Finished goods	Finished goods	21,832	15,242	
Total inventories, net	Total inventories, net	$40,227	$32,581	

7. PROPERTY AND EQUIPMENT, NET

Property and equipment consist of the following (in thousands):

	March 31, 2024	December 31, 2023
Manufacturing equipment	$ 17,178	$ 16,653
Computer hardware	5,763	5,641
Leasehold improvements	4,846	4,682
Furniture and fixtures	4,543	4,491
Assets in progress	3,431	3,135
Total property and equipment, gross	35,761	34,602
Accumulated depreciation	(15,000)	(13,673)
Total property and equipment, net	$ 20,761	$ 20,929

Depreciation expense of $1.1 million was included in operating expenses and $0.3 million was included in cost of goods sold for both the three months ended March 31, 2024 and 2023, respectively.

8. GOODWILL AND INTANGIBLE ASSETS

Goodwill

The changes in carrying amount of goodwill were as follows (in thousands):

	March 31, 2024
Balance as of December 31, 2023	$ 214,335
Foreign currency translation adjustments	(4,693)
Balance as of March 31, 2024	$ 209,642

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

6. PROPERTY AND EQUIPMENT, NET Intangible Assets

Property and equipment The intangible assets consist of the following (in thousands):

	September 30, 2023	December 31, 2022
Manufacturing equipment	$ 15,827	$ 13,585
Computer hardware	5,522	5,123
Leasehold improvements	5,248	5,040
Furniture and fixtures	4,380	4,119
Assets in progress	2,041	2,516
Capitalized software	881	—
Computer software	—	100
Total property and equipment, gross	33,899	30,483
Accumulated depreciation	(12,656)	(8,828)
Total property and equipment, net	$ 21,243	$ 21,655

	March 31, 2024		
	Gross Carrying Amount	Accumulated Amortization	Intangible Assets, Net
Developed technology	$ 147,306	$ (3,683)	$ 143,623
Capitalized software(a)	2,151	—	2,151
Total intangible assets, net	$ 149,457	$ (3,683)	$ 145,774

	December 31, 2023

	Gross Carrying Amount	Accumulated Amortization	Intangible Assets, Net
Developed technology	$ 150,649	$ (1,256)	$ 149,393
Capitalized software(a)	1,491	—	1,491
Total intangible assets, net	$ 152,140	$ (1,256)	$ 150,884

Depreciation

(a) The useful life of the capitalized software will be determined once the asset is put into service. No amortization expense has been recorded related to the capitalized software during the three months ended March 31, 2024 and 2023.

The gross carrying amount and the accumulated amortization of $1,141,000 and $947,000 the developed technology asset is subject to foreign currency translation effects. During the three months ended March 31, 2024, $2.5 million of amortization expense was included recorded in operating expenses within the condensed consolidated statements of operations and $291,000 comprehensive income (loss) related to the developed technology asset. There were no intangible assets and $223,000 was included in cost of goods sold no amortization recorded for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense March 31, 2023.

The estimated future annual amortization of $3,367,000 and $2,774,000 was included the intangible assets in operating expenses and $819,000 and $656,000 was included in cost of goods sold for service is the nine months ended September 30, 2023 and 2022, respectively. following (in thousands):

Year ending December 31:	Amount
Remainder of 2024	$ 7,365
2025	9,820
2026	9,820
2027	9,820
2028	9,820
Thereafter	96,978
Total	$ 143,623

7. 9. COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements, other than long-term real estate leases, the Company combines lease and non-lease components. The variable lease payments primarily relate to common area maintenance, property taxes, and insurance. The operating leases for facilities expire at various dates through July 2041 and some contain renewal options, the longest of which is for five years. The ROU asset and lease liability includes renewal options if the Company is reasonably certain to exercise such renewal options.

As of September 30, 2023, The interest rate implicit in lease agreements is typically not readily determinable, and as such the aggregate operating lease ROU assets and lease liabilities were $49.1 million and $32.3 million, respectively, with Company used the weighted average remaining lease term of 18.2 years. As of December 31, 2022, the aggregate operating lease ROU asset and lease liabilities were $50.7 million and $32.3 million, respectively, with the weighted average remaining lease term of 17.1 years.

As of September 30, 2023, the weighted average incremental borrowing rate used based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest rate the Company would incur to measure operating borrow on a collateralized basis, considering factors such as length of lease liabilities was 6.05%. Cash paid for amounts included in the measurement of operating lease liabilities was $866,000 and $705,000 for the three months ended September 30, 2023 and 2022, respectively, and $2,564,000 and $2,030,000 for the nine months ended September 30, 2023 and 2022, respectively.

Total lease costs are as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Operating lease cost	$ 1,137	$ 1,039	$ 3,456	$ 3,139
Short-term lease cost	22	147	85	192
Variable lease cost	402	181	809	477
Total lease costs	$ 1,561	$ 1,367	$ 4,350	$ 3,808

term.

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

The following table presents the weighted average remaining lease term and discount rate:

	March 31,	
	2024	2023
Weighted average remaining term	17.4 years	18.9 years
Weighted average discount rate	6.1 %	6.1 %

Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):

	Three Months Ended March 31,	
	2024	2023
Cash paid for amounts included in the measurement of operating lease liabilities	$ 882	$ 846

Total lease costs are as follows (in thousands):

	Three Months Ended March 31,	
	2024	2023
Operating lease cost	$ 1,175	$ 1,180
Short-term lease cost	35	22
Variable lease cost	305	166
Total lease costs	$ 1,515	$ 1,368

Future minimum lease payments under operating leases liabilities as of September 30, 2023 March 31, 2024 are as follows (in thousands):

Year ending December 31:	Year ending December 31:	Amount	Year ending December 31:	Amount
Remainder of 2023		$ 877		
2024		3,546		
Remainder of 2024				
2025	2025	3,032		
2026	2026	2,911		
2027	2027	2,978		

2028		
Thereafter	Thereafter	38,507
Total lease payments	Total lease payments	51,851
Less imputed interest	Less imputed interest	(19,594)
Total lease liabilities	Total lease liabilities	32,257
Less: lease liabilities - current portion	Less: lease liabilities - current portion	(1,630)
Lease liabilities - noncurrent portion	Lease liabilities - noncurrent portion	$30,627

The Company signed a ten-year lease for real estate in October 2023, with total undiscounted contractual payments for the three year term of the lease of approximately $7.2 million, which are is expected to commence in October the fourth quarter of 2024.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations.

The Company's amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company's amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers.

Legal Proceedings

From time to time, the Company may become is involved in legal various claims and proceedings arising out of in the ordinary course of its business. Management is currently does not aware of believe that any matters that existing claims and proceedings, including potential losses relating to such contingencies, will have a material adverse effect on the its consolidated financial position, results of operations or cash flows of the Company.

Licensed Technology flows.

In December 2021, 2023, the Company entered into received a civil investigative demand ("CID") from the U.S. Department of Justice, Civil Division, in connection with an exclusive, perpetual, royalty free, technology license agreement for use in a particular research investigation under the federal Anti-Kickback Statute and development project that requires total Civil False Claims Act (the "Investigation"). The CID requests information and documents primarily relating to meals and consulting service payments of approximately $4.2 million payable in three installments due in 2022 and 2023. provided to health care professionals. The Company accounted for is cooperating with the purchase as Investigation. The Company is unable to express a research and development expense as it was determined to have no alternative future use. As view at this time regarding the likely duration, or ultimate outcome, of September 30, 2023, there was no outstanding balance as the Company satisfied its last installment payment during Investigation or estimate the three months ended September 30, 2023. As possibility of, December 31, 2022, the outstanding balance was approximately $1.3 million which was included in accrued expenses and other current liabilities or amount or range of, any possible financial impact. Depending on the condensed consolidated balance sheets.

Sublicense Agreement

In August 2019, the Company entered into a sublicense agreement with Inceptus Medical, LLC ("Inceptus"), pursuant to which Inceptus granted to the Company a non-transferable, worldwide, exclusive sublicense to its licensed intellectual property rights related to the tubular braiding for the non-surgical removal of clots and treatment of embolism and thrombosis in human vasculature other than carotid arteries, coronary vasculature and cerebral vasculature.

Under the sublicense agreement, the Company was required to pay an ongoing quarterly administration fee, which amounted to nil and $29,000 for the three months ended September 30, 2023 and 2022 respectively, and $59,000 and $87,000 for the nine months ended September 30, 2023 and 2022 respectively. Additionally, the Company was obligated to pay an ongoing royalty ranging from 1.0% to 1.5% outcome of the net sales of products utilizing the licensed intellectual property, subject to Investigation, there may be a minimum royalty quarterly fee of $1,500. In June 2023, the sublicense agreement was terminated and the Company is no longer required to pay any ongoing administration or royalty fees following the termination.

The Company recorded royalty expense of $1,500 to cost of goods sold for both the three months ended September 30, 2023 and 2022, and recorded $5,000 and $215,000 for the nine months ended September 30, 2023 and 2022, respectively.

Self-Insured Health Plan

As of January 1, 2023, the Company implemented a self-insurance program to cover employees and their dependent health benefits, including medical, dental and vision. As part of the program, the Company also has stop-loss coverage from a third party which limits the exposure to large claims. The Company records a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, the Company utilizes an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. The assumptions are closely monitored and adjusted when necessary by changing circumstances. If the liability generated from incurred claims exceeds the expense recorded, the Company may record an additional expense. As of September 30, 2023, the Company's self-insurance liability, inclusive of administrative fees, was $2.1 million, which is included in accrued expenses and other current liabilities material impact on the condensed consolidated balance sheets. Company's business, results of operations, or financial condition.

8. 10. CONCENTRATIONS

The Company's revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three and nine months ended September 30, 2023 March 31, 2024 and 2022, 2023, there were no customers which accounted for more than 10% of the Company's revenue. As of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, there were no customers that accounted for more than 10% of the Company's accounts receivable.

No vendor accounted for more than 10% of the Company's purchases for the three and nine months ended September 30, 2023 March 31, 2024 and 2022. 2023. There were no vendors that accounted for more than 10% of the Company's accounts payable as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023.

In early 2023, certain U.S. banks failed and the regulators appointed the Federal Deposit Insurance Corporation ("FDIC") to act as receiver, which created significant market disruption and uncertainty with respect to the financial condition of the banking institutions in the U.S. While the Company does not have any direct exposure to these banks, the Company does maintain its cash and cash equivalents at multiple financial institutions in excess of the current FDIC insurance limits.

9. 11. RELATED PARTY

The Company utilizes MRI The Hoffman Group ("MRI"), a recruiting services company owned by the brother of the former Chief Executive Officer and President and current member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to $67,000 $10,000 and $70,000 $30,000 for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively, and $147,000 and $262,000 for the nine months ended September 30, 2023 and 2022, 2023, respectively, which was included recorded in SG&A expenses on within the condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, there was no balance payable to MRI.

10. 12. CREDIT FACILITY

Bank of America Credit Facility

On December 16, 2022, the Company amended its senior secured revolving credit facility with Bank of America (the "Amended "Previously Amended Credit Agreement") to, among other things, increase under which the amount available for borrowing to Company may borrow loans up to a maximum principal amount of $40.0 million and increase the optional accordion to $120.0 million. The Amended Credit Agreement matures on December 16, 2027. The amount available

Advances under the Previously Amended Credit Agreement will bear interest at a base rate per annum (the "Base ("the Base Rate") plus an applicable margin (the "Margin"). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50%, or (iii) the Bloomberg Short-Term Bank Yield Index ("the BSBY") rate based upon an interest period of one month plus 1.00%, in any case has a floor of 0%. The Margin ranges, depending on average daily availability, from 0.50% to 1.00% in the case of Prime Rate and the Federal funds rate loans, and from 1.50% to 2.00% in the case of BSBY Rate loans. As a condition to entering into the Previously Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $10,000. The Company is also required to pay an unused line fee at an annual rate of 0.25% per annum of the average daily unused portion of the aggregate revolving credit commitments under the Previously Amended Credit Agreement.

The Previously Amended Credit Agreement also includes a Letter of Credit subline facility (the "LC Facility") of up to $5.0 million. In February 2023, the Company amended the LC Facility to increase the limit to up to $10.0 million. The aggregate stated amount outstanding of letters of credit reduces the total borrowing base available under the Amended Credit Agreement. The Company is required to pay the following fees under the LC Facility: (a) a fee equal to the applicable margin in effect for BSBY loans (currently 2.25%) times the average daily stated amount of outstanding letters of credit; and (b) a fronting fee equal to 0.125% per annum on the stated amount of each letter of credit outstanding. As of September 30, 2023

On November 1, 2023, the Company had four letters further amended its credit facility (the "Amended Credit Agreement") to, among other things, increase the amount available for borrowing to up to a maximum principal amount of $75.0 million. Additionally, advances under the amended credit agreement will bear interest at the Base Rate or the BSBY rate, plus the Margin. The Margin ranges from 0.60% to 1.10% in the aggregated amount case of $2.4 million outstanding under the Base Rate loans and 1.60% to 2.10% in the case of the BSBY rate loans depending on average daily availability, in each case with a floor of 0%. As a condition of entering into the amended credit agreement, the Company was obligated to pay a nonrefundable fee of $88,000. Lastly, the Company amended the LC Facility. Facility to increase the limit up to $18.8 million. This amendment was accounted for as a debt modification in accordance ASC 470, *Debt*.

The Amended Credit Agreement contains certain customary covenants subject to certain exceptions, including, among others, the following: a fixed charge coverage ratio covenant, and limitations of indebtedness, liens, investments, asset sales, mergers, consolidations, liquidations, dispositions, restricted payments, transactions with affiliates and prepayments of certain debt. The Amended Credit Agreement also contains certain events of default subject to certain customary grace periods, including, among others, payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, bankruptcy and insolvency defaults, material judgment defaults and a change of control default.

As of September 30, 2023 March 31, 2024, the amount available to borrow under the Amended Credit Agreement is approximately $59.8 million, and the Company had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility and as a result, the Company had $16.4 million of unused letter of credit. The aggregate stated amount outstanding of letter of credits reduces the total borrowing base available under the Amended Credit Agreement.

As of March 31, 2024, there was no principal amount outstanding, and no cash was pledged under the Amended Credit Agreement, and the Company was in compliance with its covenant requirement. Obligations under the Amended Credit Agreement are secured by substantially all of the Company's assets, excluding intellectual property. The Amended Credit Agreement matures on December 16, 2027.

Deferred Financing Costs

As of March 31, 2024 and December 31, 2023, costs incurred directly related to debt are presented in other assets and are being amortized over the five-year life of the Credit Agreement on the straight-line basis as follows (in thousands):

	March 31, 2024		December 31, 2023	
Deferred financing costs	$	1,454	$	1,454
Accumulated amortization		(404)		(382)
Unamortized deferred financing costs	$	1,050	$	1,072

11. STOCKHOLDER'S 13. STOCKHOLDERS' EQUITY

Common Stock

In March 2022, the Company completed an underwritten public offering ("Follow-On Offering") of 2,300,000 shares of its common stock, including 300,000 shares sold pursuant to the underwriters' exercise of their option to purchase additional shares, at a public offering price of $81.00 per share. The Company received net proceeds of approximately $174.4 million, after deducting underwriters' discounts and commissions of $11.2 million and offering costs of $0.7 million.

Accumulated Other Comprehensive Income (Loss)

The Company's following is a summary of the changes in accumulated balances of other comprehensive income (loss) includes $1.1 million loss on foreign currency translation adjustments and less than $0.1 million of unrealized loss on investments as of September 30, 2023, and $1.0 million loss on foreign currency translation adjustments and $1.8 million of unrealized gain on investments as of December 31, 2022. There were no reclassification adjustments from accumulated other comprehensive income (loss) during for the nine three months ended September 30, 2023 March 31, 2024 and 2022. 2023 (in thousands):

	Unrealized Loss on Investments		Foreign Currency Translation		Accumulated Other Comprehensive Income (Loss)	
Balance, December 31, 2023	$	(9)	$	8,894	$	8,885
Other comprehensive loss		(4)		(7,359)		(7,363)
Balance, March 31, 2024	$	(13)	$	1,535	$	1,522

	Unrealized Gain (Loss) on Investments		Foreign Currency Translation		Accumulated Other Comprehensive Income (Loss)	
Balance, December 31, 2022	$	1,820	$	(971)	$	849
Other comprehensive (loss) income		(865)		9		(856)
Balance, March 31, 2023	$	955	$	(962)	$	(7)

12. 14. EQUITY INCENTIVE PLANS

In 2011, the Company adopted the 2011 Equity Incentive Plan (the "2011 Plan") to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees and directors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price.

In March 2020, the Company adopted the 2020 Incentive Award Plan (the "2020 Plan"), which became effective in connection with the Company's initial public offering in May 2020 ("IPO"). 2020. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2021, in an amount equal to 3% of the total number of shares of the Company's capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company's board of directors. As of September 30, 2023 March 31, 2024, there were 6,523,570 7,361,592 shares available for issuance under the 2020 Plan, including 1,620,650 1,732,872 additional shares reserved effective January 1, 2023.

2011 Equity Incentive Plan

Restricted Stock Units

In March 2019, the Company granted, under the 2011 Plan, restricted stock unit awards ("RSUs") to certain employees that vest only upon the satisfaction of both a time-based service condition and a performance-based condition that was satisfied on the effective date of the IPO of the Company's common stock. The RSUs were subject to four-year cliff vesting and vested in full in March 2023. The vesting was also subject to a market-based condition related to the value of the Company's common stock as of the vesting date. As a result of exceeding the value of the Company's common stock as set forth in the grant agreement, the maximum amount of RSUs were earned and vested during the nine months ended September 30, 2023 January 1, 2024.

RSU activity under the 2011 Equity Incentive Plan is set forth below:

	Number of Awards		Weighted Average Fair Value
Outstanding, December 31, 2022	2,712,674	$	0.17
Vested	(2,712,674)		(a)

Outstanding, September 30, 2023	—	$ —

(a)The vested RSUs will be distributed to the employees in installments. The first installment was distributed in the quarter ended March 31, 2023 with a weighted average fair value of $64.34. The second installment was distributed in the quarter ended June 30, 2023 with a weighted average fair value of $71.17. The third installment was distributed in the quarter ended September 30, 2023 with a weighted average fair value of $68.33. The remaining shares will be distributed within the quarter ended December 31, 2023.

The total fair value of RSUs vested under the 2011 Plan was $170.6 million for the nine months ended September 30, 2023. No RSUs had vested under the 2011 plan for the nine months ended September 30, 2022.

Stock Options

A summary of stock option activity under the 2011 Plan for the nine three months ended September 30, 2023 March 31, 2024 is as follows (intrinsic value values in thousands):

	Number of Awards	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)	Intrinsic Value
Outstanding, December 31, 2022	1,456,328	$ 1.93	6.20	$ 89,749
Exercised	(334,351)	$ 1.48		$ 20,583
Cancelled	(3,324)	$ 5.02		
Outstanding, September 30, 2023	1,118,653	$ 2.06	5.40	$ 70,857
Vested and exercisable at September 30, 2023	1,091,976	$ 1.95	5.40	$ 69,283
Vested and expected to vest at September 30, 2023	1,118,415	$ 2.06	5.40	$ 70,843

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)	Intrinsic Value
Outstanding, December 31, 2023	937,696	$ 2.24	5.20	$ 58,778
Exercised	(81,686)	$ 1.59		$ 4,420
Cancelled	(29)	$ 9.05		
Outstanding, March 31, 2024	855,981	$ 2.30	5.00	$ 39,102
Vested and exercisable at March 31, 2024	855,981	$ 2.30	5.00	$ 39,102
Vested and expected to vest at March 31, 2024	855,981	$ 2.30	5.00	$ 39,102

The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair market value of the Company’s common stock.

2020 Incentive Award Plan

Restricted Stock Units

RSUs Restricted stock units (“RSUs”) are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest either over a four-year period with straight-line vesting in equal amounts on a quarterly basis or and a 25% one-year cliff vesting with remaining RSUs vest or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.

RSU activity under the 2020 Plan is set forth below:

	Number of Awards	Weighted Average Fair Value
Outstanding, December 31, 2023	1,307,998	$ 67.91
Granted	619,143	48.19
Vested	(123,878)	72.49
Cancelled	(22,093)	64.11
Outstanding, March 31, 2024	1,781,170	$ 60.78

The total fair value of RSUs vested under the 2020 Plan was $8.0 million and $5.2 million for the three months ended March 31, 2024 and 2023, respectively.

RSU Performance Stock Units

During the three months ended March 31, 2024, the Company granted performance stock units (“PSUs”) to certain employees that will vest three years from the award date, based on achieving certain revenue based performance targets. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of PSUs are determined by the closing stock price of the Company’s common stock on the awards’ grant date. The stock-based compensation expense associated with PSUs is recognized on a straight-line basis based on the estimated number of awards that are expected to vest. At each reporting period, the Company monitors the probability of achieving the performance targets and adjusts the stock-based compensation expense associated with PSUs accordingly.

PSU activity under the 2020 Plan is set forth below:

	Number of Awards	Weighted Average Fair Value
Outstanding, December 31, 2023	—	$ —
Granted	90,488	55.48
Outstanding, March 31, 2024	90,488	$ 55.48

	Number of Awards	*Weighted Average Fair Value*
Outstanding, December 31, 2022	*999,215*	*$ 79.16*
Granted	*778,398*	*58.56*
Vested	*(343,689)*	*74.28*
Cancelled	*(103,667)*	*73.67*

Outstanding, September 30, 2023	*1,330,257*	*$*	*68.79*

Stock Options

The total fair value of RSUs vested under the 2020 Plan was $6.9 million and $4.5 million for the three months ended September 30, 2023 and 2022, respectively, and $21.0 million and $15.3 million for the nine months ended September 30, 2023 and 2022, respectively.

Stock options

During the nine months ended September 30, 2023, the Company granted grants non-qualified stock options to certain employees with vesting over a four-year period on a quarterly basis. The fair value of the stock options was calculated using the Black-Scholes option pricing model, which requires valuation assumptions of expected term, expected volatility, risk-free interest rate, and expected dividend yield. For the purposes of the Black-Scholes valuation model, the Company used the simplified method for determining the expected term of the granted options. The simplified method was used since the Company does not have adequate historical data to utilize in calculating the expected term of options. model. The fair value for options granted was calculated using the following weighted average assumptions:

	Nine Months Ended September 30, 2023
Expected term (in years)	4.56
Expected volatility	50.35%
Dividend yield	0.00%
Risk free interest rate	4.05%
Weighted-average fair value of options granted	$25.98 per share

	Three Months Ended March 31,	
	2024	2023
Expected term (in years)	4.48 years to 4.5 years	4.56 years
Expected volatility	48.7% to 48.9%	50.4%
Dividend yield	0.0%	0.0%
Risk free interest rate	4.2% to 4.3%	4.1%
Weighted-average fair value of options granted	$24.89 per share	$25.98 per share

A summary of stock option activities under the 2020 Plan for the nine three months ended September 30, 2023 March 31, 2024 is as follows (intrinsic value values in thousands):

	Number of Awards		Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)		Intrinsic Value
Outstanding, December 31, 2022	—	$	—	—	$	—
Granted	181,870	$	56.00			
Exercised	(916)	$	56.00		$	9
Cancelled	(9,428)	$	56.00			
Outstanding, September 30, 2023	171,526	$	56.00	6.40	$	1,612
Vested and exercisable at September 30, 2023	21,429	$	56.00	6.20	$	201
Vested and expected to vest at September 30, 2023	158,495	$	56.00	6.40	$	1,490

	Number of Options		Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)		Intrinsic Value
Outstanding, December 31, 2023	166,203	$	56.00	6.10	$	1,483
Granted	210,188	$	54.83			
Exercised	(270)	$	56.00		$	—
Cancelled	(541)	$	56.00			
Outstanding, March 31, 2024	375,580	$	55.35	6.40	$	209
Vested and exercisable at March 31, 2024	39,985	$	56.00	5.90	$	—
Vested and expected to vest at March 31, 2024	341,226	$	55.37	6.40	$	184

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

Employee Stock Purchase Plan

In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan ("ESPP"), which became effective on the date the ESPP was amended and restated in October 2020 adopted by the Compensation Committee of the Company's board of directors. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Compensation Committee, in its sole discretion. The number of shares available for issuance under the ESPP increases automatically on January 1 of each calendar year of the Company beginning in 2021 and ending in 2030, in an amount equal to the lesser of (i) 1% of the aggregate number of outstanding shares of the Company's common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares determined by the Company's board of directors.

The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:

		Nine Months Ended September 30,				
		2023	2022			
	Three Months Ended March 31,				Three Months Ended March 31,	
	2024				2024	2023
Expected term (in years)	Expected term (in years)	0.5	0.5	Expected term (in years)	0.50	0.50

Expected volatility	Expected volatility	42.08% - 49.89%	56.09% - 72.78%	Expected volatility	60.8%	49.9%
Dividend yield	Dividend yield	0.00 %	0.00 %	Dividend yield	0.0%	0.0%
Risk free interest rate	Risk free interest rate	4.79% - 5.54%	0.48% - 2.96%	Risk free interest rate	5.2%	4.8%

As of September 30, 2023 March 31, 2024, a total of (i) 423,109 505,925 shares of common stock, including 118,494 shares purchased in July 2023 and 86,051 82,816 shares purchased in January 2023, 2024, have been purchased under the ESPP, and (ii) 2,103,629 2,598,437 shares of common stock are reserved under the ESPP for future purchases, including 540,217 577,624 additional shares, which were automatically added to the reserve on January 1, 2023 January 1, 2024 pursuant to the terms of the ESPP.

Stock-based Compensation Expense

Total compensation cost for all share-based payment arrangements recognized, including $0.7 $1.0 million and $0.8 million for both the three months ended September 30, 2023 March 31, 2024 and 2022, respectively, and $2.9 million and $2.5 million for nine months ended September 30, 2023 and 2022, 2023, respectively, of stock-based compensation expense related to the ESPP, was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	2024			
	2024			
	2024			
Cost of goods sold				
Cost of goods sold				
Cost of goods sold / Cost of goods sold	$ 393	$ 386	$ 1,232	$ 1,126
Research and development / Research and development	1,587	1,051	4,981	3,143
Research and development				
Research and development				
Selling, general and administrative / Selling, general and administrative	7,864	5,919	24,323	16,806
	$ 9,844	$ 7,356	$ 30,536	$ 21,075
Selling, general and administrative				
Selling, general and administrative				
Total stock-based compensation expense				
Total stock-based compensation expense				
Total stock-based compensation expense				

Total stock-based compensation expense costs as of September 30, 2023 March 31, 2024 related to all non-vested awards to be recognized in future periods was $78.9 million $99.9 million and is expected to be recognized over the remaining weighted average period of 2.7 2.8 years.

INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

13. 15. INCOME TAXES

The following table reflects the Company's provision for income taxes for the periods indicated (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Income (loss) before income taxes	$ 5,590	$ (9,313)	$ 7,420	$ (21,377)
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	Three Months Ended March 31,			
	2024			
	2024			
	2024			
Loss before income taxes				
Loss before income taxes				
Loss before income taxes				
Provision for income taxes Provision for income taxes	2,428	840	4,391	2,092
Net income (loss)	$ 3,162	$ (10,153)	$ 3,029	$ (23,469)
Provision for income taxes				
Provision for income taxes				
Net loss				
Net loss				
Net loss				
Provision for income taxes as a percentage of income (loss) before income taxes Provision for income taxes as a percentage of income (loss) before income taxes	43.4%	(9.0%)	59.2 %	(9.8 %)
Provision for income taxes as a percentage of income (loss) before income taxes				
Provision for income taxes as a percentage of income (loss) before income taxes				

The effective tax rate for all periods is driven by pre-tax income/(loss), business credits, equity compensation, state taxes, and the change in valuation allowance. The Company's income tax provision for interim reporting periods historically has been calculated by applying an estimate of the annual effective income tax rate for the full year to "ordinary" income (loss) for the interim reporting period. In addition, the tax effects of certain significant or unusual items are recognized discretely in the quarter in which they occur. For the nine three months ended September 30, 2023 March 31, 2024, the Company calculated the income tax provision using this methodology. For the nine three months ended September 30, 2022 March 31, 2023, a discrete effective income tax rate method was used as if the interim year to date period was an annual period.

For tax years beginning after December 31, 2021, certain research and development costs are required to be capitalized and amortized over a five year period under the Tax Cuts and Jobs Act, which was signed into law December 22, 2017. The Company has reviewed and incorporated this change, which will impact the expected U.S. federal and state tax expense and cash taxes to be paid for the tax year ending December 31, 2023.

Valuation Allowance

ASC 740, *Income Taxes*requires that the tax benefit of net operating losses, or NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." not". Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryback or carryforward periods. As of December 31, 2022 December 31, 2023, the Company maintained was in a full net deferred tax liability position due to the LimFlow acquisition. However, a valuation allowance of $30.3 million was maintained against the Company's net certain deferred tax assets. As of September 30, 2023 March 31, 2024, the Company believes that the net deferred tax assets are currently not considered more likely than not to be realized and, accordingly, has maintained maintains a full valuation allowance against its certain deferred tax assets. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Any release of the valuation allowance may will result in a material benefit recognized in the quarter of release.

Uncertain Tax Positions

The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to credit carryforwards that are available to offset the uncertain tax positions. It is not expected that there will be a significant change in the uncertain tax position in the next twelve 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no income tax examinations in progress. The statute of limitations for tax years ended after December 31, 2019 December 31, 2020, December 31, 2018 December 31, 2019, and December 31, 2017 December 31, 2020 are open for federal, and state, and foreign tax purposes, respectively.

14. 16. RETIREMENT PLAN

In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributes contributed a $1.00 match for every $1.00 contributed by a participating employee up to the greater of $3,000 or 4% of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. On January 1, 2024, the plan was amended to provide that the Company contributes a $1.00 match for every $1.00 contributed by a participating employee for up to 5% of eligible compensation. The plan also includes a limit of $15,000 per individual of employer match, with such Company's contributions becoming fully vested immediately. Matching contribution expense was $2.0 million $4.0 million and $1.7 million $2.7 million for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively, and $6.9 million and $6.2 million for the nine months ended September 30, 2023 and 2022, 2023, respectively.

15. 17. NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed using the treasury stock method by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, shares from common stock options RSUs and ESPP equity awards are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.

The components of net income (loss) per share are as follows (in thousands, except per share amounts):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Numerator:				
Net income (loss)	$ 3,162	$ (10,153)	$ 3,029	$ (23,469)
Denominator:				
Weighted average number of common shares outstanding - basic	57,384,884	53,491,625	56,478,317	52,552,662
Common stock equivalents from outstanding options	1,102,642	—	1,173,190	—
Common stock equivalents from unvested RSUs	94,531	—	832,873	—
Common stock equivalents from ESPP	6,395	—	11,541	—
Weighted average number of common shares outstanding - diluted	58,588,452	53,491,625	58,495,921	52,552,662
Net income (loss) per share:				
Basic	$ 0.06	$ (0.19)	$ 0.05	$ (0.45)
Diluted	$ 0.05	$ (0.19)	$ 0.05	$ (0.45)

The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net income (loss) loss per share due to their anti-dilutive effect:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Common stock options	171,526	1,838,562	1,290,179	1,838,562
RSUs	555,468	3,694,930	1,332,500	3,694,930
	726,994	5,533,492	2,622,679	5,533,492

16. SUBSEQUENT EVENTS

On November 1, 2023, the Company announced that it entered into a share purchase agreement (the “Purchase Agreement”) to acquire LimFlow, S.A. (“LimFlow”), a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (the “LimFlow Acquisition”). Under the terms of the Purchase Agreement, the Company will pay $250 million in cash at closing, subject to adjustment based on the working capital, indebtedness, cash and transaction expenses of LimFlow. Additional contingent payments of up to $165 million will be payable depending on the achievement of certain commercial and reimbursement milestones. The Company expects to fund this acquisition via its existing cash and the availability under its credit facility. The LimFlow Acquisition is expected to close in the fourth quarter of the year endedDecember 31, 2023 and is subject to certain customary closing conditions set forth in the Purchase Agreement.

On November 1, 2023, the Company amended its credit facility to, among other things, increase the amount available for borrowing to up to a maximum principal amount of $75.0 million. Additionally, advances under this amended credit agreement will bear interest at a base rate per annum (“the Base Rate”) or the Bloomberg Short-Term Bank Yield Index (“the BSBY”) rate, plus an applicable margin (“the Margin”). The Margin ranges from 0.60% to 1.10% in the case of the Base Rate loans and 1.60% to 2.10% in the case of the BSBY rate loans depending on average daily availability, in each case with a floor of 0%. As a condition of entering into this amended credit agreement, the Company was obligated to pay a nonrefundable fee of $88,000. Lastly, the Company amended the LC Facility to increase the limit to up to $18.8 million.

	Three Months Ended March 31,	
	2024	2023
Stock options	1,231,561	1,427,294
Equity awards	1,871,658	1,497,342
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect	3,103,219	2,924,636

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes thereto for the year ended December 31, 2022 December 31, 2023, included in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023. In addition to historical financial information, the following discussion contains forward-looking statements that are based upon current plans, expectations and beliefs that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023. Please also see the section titled “Cautionary Note Regarding Forward-Looking Statements.” Statements” herein.

OVERVIEW

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism (VTE), and beyond. four other disease states. We are just getting started.

Our solutions (“products”) primarily consist We purpose build a variety of our ClotTriever and FlowTriever systems, which are products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems devices and their accessories to address the unique characteristics of specific disease states. In addition, in November 2023, we acquired LimFlow, a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (CLTI). CLTI is an advanced stage of peripheral artery disease that are purpose-built for is associated with increased mortality, risk of amputation and impaired quality of life. The LimFlow system utilizes transcatheter arterialization of deep veins (TADV) to bypass blocked arteries in the specific characteristic leg and deliver oxygenated blood back into the foot via the veins in CLTI patients. The results of operations of LimFlow have been included in our condensed consolidated financial statements from the date of the venous system acquisition.

Together, our devices and systems provide solutions to address the treatment of the two distinct manifestations of venous thromboembolism, or VTE - following disease states: deep vein thrombosis, or DVT, and pulmonary embolism, or PE. chronic venous disease, CLTI, acute limb ischemia (ALI) and dialysis access management.

We believe our mission-focused and highly-trained commercial organization provides a significant competitive advantage. Our ClotTriever system is FDA-cleared for the treatment of DVT, most important relationships are between our sales representatives and our FlowTriever system is treating physicians, which include interventional cardiologists, interventional radiologists and vascular surgeons. We recruit sales representatives who have substantial and applicable medical device and/or sales experience. Our front-line sales representatives typically attend procedures, which puts us at the first thrombectomy system FDA-cleared for intersection of the treatment of PE patients and is also FDA-cleared for clot in transit in physicians. We have developed systems and processes to harness the right atrium. Our information gained from these relationships and we leverage this information to rapidly iterate our solutions, also consist of introduce and execute physician education and training programs and scale our InThrill system, sales organization. We market and sell our solutions to hospitals, which is FDA-cleared for the removal of thrombus from the peripheral vasculature and designed for smaller vessels, and our ProTrieve sheath, which is FDA-cleared for removal of thrombus from the peripheral vasculature through aspiration. During the nine months ended September 30, 2023, we released the RevCore thrombectomy catheter, which is an FDA-cleared mechanical thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is FDA-cleared for PE and venous thrombus removal, and ClotTriever Bold catheter, which is FDA-cleared for DVT and the removal of acute and chronic clots in the peripheral vasculature. In addition, we released ClotTriever XL, which is a purpose-built FDA-cleared catheter for efficient clot removal with minimal blood loss.

In March 2022, we completed an underwritten public offering, or the Follow-On Offering, of 2,300,000 shares of common stock, at a price of $81.00 per share. We received net proceeds of approximately $174.4 million, after deducting underwriters' discounts and commissions and offering costs. are reimbursed by various third-party payors.

As of September 30, 2023 March 31, 2024, we had cash, cash equivalents, restricted cash and short-term investments of $351.3 million $101.8 million, no long-term debt outstanding and an accumulated deficit of $43.8 $72.7 million.

For the three months ended September 30, 2023 March 31, 2024, we generated $126.4 million $143.2 million in revenues with a gross margin of 88.5% 86.8% and net income loss of $3.2 million $24.2 million, as compared to revenues of $96.2 million $116.2 million with a gross margin of 88.5% 88.2% and net loss of $10.2 million $2.2 million for the three months ended September 30, 2022.

For the nine months ended September 30, 2023, we generated $361.5 million in revenues with a gross margin of 88.4% and net income of $3.0 million, as compared to revenues of $275.7 million with a gross margin of 88.6% and net loss of $23.5 million for the nine months ended September 30, 2022 March 31, 2023.

Revenue

We derived substantially all our revenue from the sale of our ClotTriever and FlowTriever systems VTE products directly to hospitals primarily located in the United States. hospitals. Our customers typically purchase our products through an initial stocking order, and then reorder replenishment inventory as procedures are performed. No single customer accounted for 10% or more of our revenue during the three and nine months ended September 30, 2023 March 31, 2024 and 2022. 2023. We expect our revenue to increase in absolute dollars as we expand our offerings, globally, grow our the sales organization and sales territories, add customers, expand the base of physicians that are trained to use who gain experience with using our products, expand awareness of our products with new and existing customers and as physicians perform more procedures using our products.

We disaggregate revenue between VTE and Emerging Therapies markets. VTE comprises revenue from the sale of our ClotTriever and FlowTriever systems. Emerging Therapies comprises revenues from the sale of our solutions addressing chronic venous disease, CLTI, small vessel thrombosis and arterial thromboembolism. Revenue from ClotTriever VTE and other systems and FlowTriever system Emerging Therapies are as a percentage of total revenue is as follows: follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
ClotTriever and other systems	32 %	31 %	34 %	32 %
FlowTriever system	68 %	69 %	66 %	68 %

	Three Months Ended March 31,	
	2024	2023
VTE	$ 137,193	$ 114,058
Emerging Therapies	6,001	2,109
Total Revenue	$ 143,194	$ 116,167

RESULTS OF OPERATIONS

Comparison of the three months ended September 30, 2023 March 31, 2024 and 2022 2023

The following table sets forth the components of our unaudited condensed consolidated statements results of operations in dollars and as percentage of revenue for the periods presented (dollars in thousands):

		Three Months Ended September 30,				
		2023	%	2022	%	Change $
	Three Months Ended March 31,			Three Months Ended March 31,		
	2024					Change $
Revenue						
Revenue						
Revenue	Revenue	$126,366	100.0 %	$ 96,204	100.0 %	$30,162
Cost of goods sold	Cost of goods sold	14,477	11.5 %	11,064	11.5 %	3,413
Gross profit	Gross profit	111,889	88.5 %	85,140	88.5 %	26,749
Operating expenses	Operating expenses					
Research and development	Research and development	21,492	17.0 %	19,105	19.9 %	2,387
Research and development						
Research and development						
Selling, general and administrative	Selling, general and administrative	88,284	69.9 %	75,833	78.8 %	12,451
Change in fair value of contingent consideration						
Amortization of intangible asset						
Acquisition-related expenses						
Total operating expenses	Total operating expenses	109,776	86.9 %	94,938	98.7 %	14,838
Income (loss) from operations		2,113	1.6 %	(9,798)	(10.2)%	11,911

Loss from operations						
Other income (expense)	Other income (expense)					
Interest income						
Interest income						
Interest income	Interest income	4,202	3.3 %	618	0.6 %	3,584
Interest expense	Interest expense	(43)	— %	(74)	(0.1)%	31
Other expense	Other expense	(682)	(0.5)%	(59)	(0.1)%	(623)
Total other income	Total other income	3,477	2.8 %	485	0.4 %	2,992
Income (loss) before income taxes		5,590	4.4 %	(9,313)	(9.8)%	14,903
Loss before income taxes						
Provision for income taxes	Provision for income taxes	2,428	1.9 %	840	0.9 %	1,588
Net income (loss)		$ 3,162	2.5 %	$(10,153)	(10.7)%	$13,315
Net loss						

Revenue. Revenue increased $30.2 million $27.0 million, or 31.4% 23.3%, to $126.4 million $143.2 million during the three months ended September 30, 2023 March 31, 2024, compared to $96.2 million $116.2 million during the three months ended September 30, 2022 March 31, 2023. The increase in revenue was primarily due to an increase in the number of products sold as we expanded our sales territories, opened new accounts and achieved deeper penetration of our products into existing accounts, and introduced new products.

Cost of Goods Sold. Cost of goods sold increased $3.4 million, or 30.8%, to $14.5 million during the three months ended September 30, 2023, compared to $11.1 million during the three months ended September 30, 2022. This increase was primarily due to the increase in the number of products sold and additional manufacturing overhead costs to support anticipated future growth.

Gross Margin. Gross margin for the three months ended September 30, 2023 and 2022 remained flat at 88.5%.

Research and Development Expenses (“R&D”). R&D expenses increased $2.4 million, or 12.5%, to $21.5 million during the three months ended September 30, 2023, compared to $19.1 million during the three months ended September 30, 2022. The increase in R&D expenses was primarily due to increases of $1.5 million of material and supplies related expenses and $0.8 million of personnel-related expenses.

Selling, General and Administrative Expenses (“SG&A”). SG&A expenses increased $12.5 million, or 16.4%, to $88.3 million during the three months ended September 30, 2023, compared to $75.8 million during the three months ended September 30, 2022. The increase in SG&A expenses was primarily due to increases of $9.7 million in personnel-related expenses as a result of increased headcount and increased commissions due to higher revenue, $3.0 million of expenses related to professional fees, $0.6 million of material and supplies related expenses, and $0.3 million of facilities-related expenses, partially offset by decreases of $0.8 million in sales and marketing related expenses, and $0.4 million of expenses related to insurance costs.

Interest Income. Interest income increased $3.6 million to $4.2 million during the three months ended September 30, 2023, compared to $0.6 million during the three months ended September 30, 2022. The increase in interest income was primarily due to an increase in interest rates as well as an increase in the average balance of our short-term investments during the three months ended September 30, 2023 compared to the three months ended September 30, 2022.

Interest Expense. Interest expense decreased to $43,000 during the three months ended September 30, 2023, compared to $74,000 during the three months ended September 30, 2022.

Other Expense. Other expense was $0.7 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively. The increase in other expense was primarily due to an impairment loss related to our strategic investment of $0.6 million, and foreign currency transaction losses.

Income Taxes. Income taxes increased $1.6 million to $2.4 million during the three months ended September 30, 2023, compared to $0.8 million during the three months ended September 30, 2022. The increase in income taxes primarily relates to an increase in the current year U.S. federal and state income taxes due to an increase in the U.S. pre-tax book income for the three months ended September 30, 2023.

Comparison of the nine months ended September 30, 2023 and 2022

The following table sets forth the components of our unaudited condensed consolidated statements of operations in dollars and as percentage of revenue for the periods presented (dollars in thousands):

	Nine Months Ended September 30,				
	2023	%	2022	%	Change $
Revenue	$ 361,538	100.0 %	$ 275,700	100.0 %	$ 85,838
Cost of goods sold	42,062	11.6 %	31,378	11.4 %	10,684
Gross profit	319,476	88.4 %	244,322	88.6 %	75,154
Operating expenses					
Research and development	64,641	17.9 %	53,809	19.5 %	10,832
Selling, general and administrative	259,570	71.8 %	212,721	77.2 %	46,849
Total operating expenses	324,211	89.7 %	266,530	96.7 %	57,681
Loss from operations	(4,735)	(1.3 %)	(22,208)	(8.1 %)	17,473
Other income (expense)					
Interest income	12,899	3.6 %	882	0.3 %	12,017
Interest expense	(127)	— %	(220)	(0.1 %)	93
Other (expense) income	(617)	(0.2 %)	169	0.1 %	(786)
Total other income	12,155	3.4 %	831	0.3 %	11,324
Income (loss) before income taxes	7,420	2.1 %	(21,377)	(7.8 %)	28,797
Provision for income taxes	4,391	1.2 %	2,092	0.8 %	2,299
Net income (loss)	$ 3,029	0.9 %	$ (23,469)	(8.6 %)	$ 26,498

Revenue. Revenue increased $85.8 million, or 31.1%, to $361.5 million during the nine months ended September 30, 2023, compared to $275.7 million during the nine months ended September 30, 2022. The increase in revenue was due primarily to an increase in the number of products sold as we expanded our sales territories, opened new accounts and achieved deeper penetration of our products into existing accounts, and introduced new products.

Cost of Goods Sold. Cost of goods sold increased $10.7 million, $5.2 million, or 34.0% 37.5%, to $42.1 million $18.9 million during the nine three months ended September 30, 2023 March 31, 2024, compared to $31.4 million $13.7 million during the nine three months ended September 30, 2022 March 31, 2023. This increase was primarily due to the increase in the number of products sold and additional manufacturing overhead costs to support anticipated future growth.

Gross Margin. Gross margin for the nine three months ended September 30, 2023 March 31, 2024 decreased to 88.4% 86.8%, compared to 88.6% 88.2% for the nine three months ended September 30, 2022 March 31, 2023, primarily due to increasing internationalization of the increase in business, ramp up costs associated with the addition of new components offered under our FlowTriever system price, partially offset by manufacturing efficiencies. products, and product mix.

Research and Development Expenses (“R&D”). R&D expenses increased $10.8 million, $4.8 million, or 20.1% 21.8%, to $64.6 million $26.9 million during the nine three months ended September 30, 2023 March 31, 2024, compared to $53.8 million $22.1 million during the nine three months ended September 30, 2022 March 31, 2023. The increase in R&D expenses was primarily due to increases of $6.4 million of personnel-related expenses, $4.0 $1.5 million of material and supplies related expenses, $0.9 $1.3 million of clinical and regulatory expenses, $0.8 million in professional fees, $0.6 million in personnel-related expenses, and $0.3 million in software costs and depreciation expenses, in support of our growth drivers to develop new products and build the clinical evidence base, partially offset by a decrease of $1.1 million of expenses related to professional fees. base.

Selling, General and Administrative Expenses (“SG&A”). SG&A expenses increased $46.8 million, $17.4 million, or 22.0% 20.3%, to $259.6 million $103.1 million during the nine three months ended September 30, 2023 March 31, 2024, compared to $212.7 million $85.7 million during the nine three months ended September 30, 2022 March 31, 2023. The increase in SG&A expenses was primarily due to increases of $42.2 $13.1 million in personnel-related expenses as a result of increased headcount and increased commissions due to higher revenue, $2.8 $2.7 million of expenses related to professional fees, $1.9 million in travel and related expenses, $1.6 $1.5 million of materials and supplies, $0.7 travel related costs.

Other Operating Expenses. Other operating expenses increased by $6.3 million due to the change in fair value adjustment of our contingent consideration liability, $2.5 million due to amortization expense related to facilities-related the acquired intangible asset, and $2.8 million due to the acquisition-related expenses, which include integration and $0.6 million of retention costs, during the three months ended March 31, 2024.

software costs*Other income (expense).* Other income (expense) consists primarily of interest income, interest expense and depreciation expenses, partially offset by decreases of $2.1 million in sales foreign currency transaction gains and marketing related expenses and $1.0 million of insurance related expenses.

Interest Income. losses. Interest income increased $12.0 million decreased by $3.0 million to $12.9 million $1.2 million during the nine three months ended September 30, 2023 March 31, 2024, compared to $0.9 million $4.1 million during the nine three months ended September 30, 2022 March 31, 2023. The increase decrease in interest income was primarily due to an increase lower cash balances invested in interest rates as well as an increase in the average balance of our short-term investments in debt securities during the nine three months ended September 30, 2023 March 31, 2024 compared to the nine three months ended September 30, 2022 March 31, 2023.

Interest Expense. Interest expense decreased to $127,000 during the nine months ended September 30, 2023, compared to $220,000 during the nine months ended September 30, 2022.

Other (Expense) Income. Other expense was $0.6 million and other income was $0.2 million for the nine months ended September 30, 2023 and September 30, 2022, respectively. The change in other (expense) income was primarily due to an impairment loss related to our strategic investment of $0.6 million, and foreign currency transaction losses.

REFINITIV

Income Taxes. Income taxes increased $2.3 million $7.1 million to $4.4 million for $8.1 million during the nine three months ended September 30, 2023 March 31, 2024, compared to $2.1 million $1.0 million during the nine three months ended September 30, 2022 March 31, 2023. The increase in income taxes was primarily due to the Company calculating the income taxes primarily relates to tax provision by applying an increase in the current year U.S. federal and state income taxes due to an increase in the U.S. pre-tax book income estimated annual effective tax rate for the nine three months ended September 30, 2023 March 31, 2024, whereas the discrete effective tax rate method was used for the three months ended March 31, 2023. Beginning in 2024, many countries are implementing some or all of the Organisation for Economic Co-operation and Development's Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countries' implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.

LIQUIDITY AND CAPITAL RESOURCES

To date, our primary sources of capital have been the net proceeds we received through private placements of preferred stock, debt financing agreements, the sale of common stock in our IPO completed on May 27, 2020 and the Follow-On Offering completed in March 2022, and revenue from the sale of our products. products and existing cash and cash equivalent balances. As of September 30, 2023 March 31, 2024, we had cash and cash equivalents of $89.2 million $66.7 million, restricted cash of $0.5 million and short-term investments in debt securities of $262.1 $34.6 million. We maintain cash and cash equivalents with financial institutions in excess of insured limits.

On November 1, 2023

As of March 31, 2024, we announced that we entered into a Purchase Agreement the fair value of contingent consideration related to acquire LimFlow. Under our acquisition of LimFlow was $72.2 million, of which $9.3 million was recorded within accrued expenses and other current liabilities and $62.9 million was recorded within other long-term liabilities in the terms condensed consolidated balance sheets. The contingent payments related to certain commercial and reimbursement milestones can be up to $165.0 million which includes (i) up to $140.0 million based on net revenue generated from the sale of the Purchase Agreement, we will pay $250 million in cash at closing, subject to adjustment based on LimFlow system for the working capital, indebtedness, cash years 2024 through 2026 and transaction expenses of LimFlow. Additional contingent payments of (ii) up to $165 $25.0 million will be payable depending based on the achievement of certain commercial and reimbursement milestones. We expect milestones related to fund this acquisition via our existing cash and the availability under our credit facility. The LimFlow Acquisition is System. Revenue-based milestone payments are expected to close be due in the fourth first quarter of each of 2025, 2026 and 2027. The timing of reimbursement-based milestone payments is dependent on the year ended December 31, 2023 achievement of such milestones and is subject to certain customary closing other conditions set forth in the Purchase Agreement. share purchase agreement with LimFlow. As of March 31, 2024, we have not made any payments related to the contingent consideration. For additional information about the acquisition, see Note 3. Business Combination, which is included in "Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)".

In December 2022, we amended the our revolving Credit Agreement governing our senior secured revolving credit facility with Bank of America (" (as amended, the "Previously Amended Credit Agreement") to, among other things, increase the amount available which provides for borrowing to loans up to a maximum of $40.0 million and increase increases the optional accordion to $120.0 million. As of September 30, 2023, we had no principal outstanding under the Amended Credit Agreement and the amount available to borrow was approximately $37.6 million. The Previously Amended Credit Agreement also includes included a LC Facility Letter of Credit subline facility (the "LC Facility") of up to $5.0 million. In February 2023, we amended the LC Facility to increase the limit to up to $10.0 million. The aggregate stated amount outstanding of letters of credit reduces the total borrowing base available under In November 2023, we further amended the Amended Credit Agreement, and is subject to certain fees. As of September 30, 2023, we had four letters of credit as defined in the aggregated amount of $2.4 million outstanding under the LC Facility. For additional information about the Amended Credit Agreement, see note 10. Note 12. Credit Facility to our condensed consolidated financial statements, which is included in "Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)" of this report. On November 1, 2023, we amended our credit facility to, among other things, increase the amount available for borrowing to up to a maximum principal amount of $75.0 million. We also amended the LC Facility to increase the limit to up to $18.8 million. As of March 31, 2024, we had no principal outstanding under the Amended Credit Agreement and the amount available to borrow was approximately $59.8 million. As of March 31, 2024, we had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility and as a result, we had $16.4 million of unused letter of credit. The aggregate stated amount outstanding of letter of credits reduces the total borrowing base available under the Amended Credit

Agreement and is subject to certain fees. For additional information about the Amended Credit Agreement, see Note 12. Credit Facility, which is included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)”.

In October 2023, we signed a ten-year lease for real estate with total undiscounted contractual payments for the three-year term of the lease of approximately $7.2 million, which are expected to commence in October the fourth quarter of 2024.

Our other short-term and long-term material cash requirements, from known contractual obligations as of September 30, 2023 March 31, 2024, include contingent consideration liability, operating lease liabilities and uncertain tax positions, as discussed in note 7. Note 3. Business Combination, Note 4. Fair Value Measurements, Note9. Commitments and Contingencies and note 13. Note 15. Income Taxes to our condensed consolidated financial

statements section of this report, which is are included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)” of this report.

Based on our current planned operations, we anticipate that our cash and cash equivalents, short-term investments and available borrowings under our Amended Credit Agreement will be sufficient to fund these cash requirements and our operating expenses for at least the next 12 months. Our primary short-term needs for capital for our current planned operations, which are subject to change, include:

- support of commercialization efforts to expand our sales force along with expanding into new markets, and developing products to enhance performance and address unmet market needs;
- the continued advancement of research and development including clinical study activities; and
- potential expansion needs of our facilities.

If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, we may seek to sell additional common or preferred equity or convertible debt securities, enter into an additional credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available on reasonable terms, or at all. In addition, market conditions impacting financial institutions could impact our ability to access some or all of our cash and cash equivalents, and we may be unable to obtain alternative funding when and as needed on acceptable terms, if at all.

CASH FLOWS

The following table summarizes our cash flows for each of the periods indicated (in thousands):

		Nine Months Ended September 30,		
		2023	2022	
	Three Months Ended March 31,		Three Months Ended March 31,	
	2024		2024	2023
Net cash provided by (used in):	Net cash provided by (used in):			

Operating activities			
Operating activities			
Operating activities	Operating activities	$23,686	$(25,227)
Investing activities	Investing activities	1,698	(161,969)
Financing activities	Financing activities	3,581	178,827
Effect of foreign exchange rate changes on cash and cash equivalents		(5)	(855)
Net increase (decrease) in cash and cash equivalents		$28,960	$ (9,224)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash			
Net increase (decrease) in cash, cash equivalents, and restricted cash			

Net cash used in operating activities

Net cash provided by used in operating activities for the nine three months ended September 30, 2023 March 31, 2024 was $23.7 $12.3 million, consisting primarily of a net income loss of $3.0 million $24.2 million and non-cash charges of $27.6 million $23.3 million, offset by a net change in our net operating assets and liabilities of $6.9 million $11.4 million. The non-cash charges primarily consisted of stock-based compensation expense of $30.5 $12.9 million, change in fair value of contingent consideration liability of $6.3 million, depreciation and amortization of $4.2 $3.9 million, and amortization of the right-of-use assets of $3.1 $0.8 million, partially offset by amortization of premium and discount on marketable securities of $11.4 $0.6 million. The change in our net operating assets and liabilities was primarily due to increases in accounts receivable of $11.6 $8.7 million, inventories of $7.8 million, payroll-related accruals, accrued expenses and other liabilities of $7.2 $2.1 million, and accounts payable of $2.4 $1.5 million, in addition to a decrease in prepaid payroll-related accruals, accrued expenses deposits and other assets of $4.3 million and operating lease liabilities of $1.0 million.

Net cash used in operating activities for the nine three months ended September 30, 2022 March 31, 2023 was $25.2 $2.0 million, consisting primarily of net loss of $23.5 million $2.2 million and a net change decrease in our net operating assets and liabilities of $28.5 million, $9.4 million, offset by non-cash charges of $26.8 million. $9.6 million. The change decrease in our net operating assets and liabilities was primarily due to increases decreases in accrued liabilities and accounts payable of $7.8 million and $0.3 million, respectively, due to the timing of payments and growth of our operations, a decrease in lease prepayments for lessor's owned leasehold improvements of $0.5 million and a decrease in operating lease liabilities of $0.4 million, coupled with an increase in inventories of $3.8 million, offset by decreases in accounts receivable of

$12.2 million, inventories of $8.7 million, $2.8 million and prepaid and other assets of $1.5 million, in addition to a decrease in lease prepayments for lessor's owned leasehold

improvements of $4.5 million. $0.5 million. The non-cash charges primarily consisted of $21.1 million in stock-based compensation expense $3.4 million in depreciation, and $1.8 million in of $10.3 million, amortization of the right-of-use assets. assets of $1.6 million and depreciation of $1.3 million, partially offset by amortization of premium and discount on marketable securities of $3.8 million.

Net cash used in investing activities

Net cash provided by investing activities for the nine three months ended September 30, 2023 March 31, 2024 was $1.7 $39.2 million, consisting of purchases of $394.5 $21.5 million of short-term investments, $3.8 $1.3 million of property and equipment, and $0.6 million of other investments, offset by maturities of short-term investments of $400.6 million.

Net cash used in investing activities for the nine months ended September 30, 2022 was $162.0 million, consisting of purchases of $332.1 million of short-term investments, $5.7 million of other investments, and $8.2 million of property and equipment, offset by maturities of short-term investments of $184.0 million. $62.6 million.

Net cash used in investing activities for the three months ended March 31, 2023 was $4.0 million, consisting of $122.1 million purchases of short-term investments, $1.0 million of purchases of property and equipment, and $0.3 million of purchases of other investments, offset by maturities of short-term investments of $119.3 million.

Net cash provided by financing activities

Net cash provided by financing activities in the nine three months ended September 30, 2023 March 31, 2024 was $3.6 $1.0 million, consisting of $9.9 $4.0 million of proceeds from the issuance of common stock under our employee stock purchase plan, and $0.5 million of proceeds from the exercise of stock options, offset by $6.9 $3.1 million of tax payments related to vested RSUs. equity awards.

Net cash provided by financing activities in the nine three months ended September 30, 2022 March 31, 2023 was $178.8 $2.5 million, consisting of $174.4 million of net proceeds from the issuance of common stock in the Follow-On Offering, net of issuance costs of $11.9 million, $8.4 million of $4.2 million proceeds from the issuance of common stock under our employee stock purchase plan and $0.6 million $0.2 million of proceeds from the exercise of stock options, offset by $4.6 million $1.9 million of tax payments related to vested RSUs. equity awards.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Other than the accounting policy changes discussed in note 2. Summary of Significant Accounting Policies to our condensed consolidated financial statements, which is included in "Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)", there There have been no significant changes in our critical accounting policies during the nine three months ended September 30, 2023 March 31, 2024, as compared to the critical accounting policies disclosed in under "Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, filed with the SEC on February 27, 2023 February 29, 2024.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, filed with the SEC on February 27, 2023 February 29, 2024 under "Part II, Item 7. 7A. Quantitative and Qualitative Disclosures about Market Risk." Risk".

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures

Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of September 30, 2023 March 31, 2024. Based on such evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of September 30, 2023 March 31, 2024, these disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management as appropriate to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any control and procedure, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in internal control over financial reporting

During the quarter ended September 30, 2023 March 31, 2024, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

We are not subject to any See Note 9. Commitments and Contingencies, which is included in "Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)" for information regarding material legal proceedings.

Item 1A. RISK FACTORS

For a discussion of risk factors that may affect our potential risks business and uncertainties, financial results, see the information in Part I, "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, filed with the SEC on February 29, 2024. As of the date of this Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

Insider Trading Arrangements

As previously disclosed, in connection with grants made under the 2011 Equity Incentive Plan for RSUs, certain RSUs were vested in March 2023 and will be distributed in installments to the employees. In November 2022, to ensure that we would receive the funds required to pay all tax obligations due in connection with the distribution and settlement of these previously-vested RSUs on a timely basis, Mr. Bill Hoffman, a member of our Board of Directors, Mr. Andrew Hykes, Chief Executive Officer and President, and Dr. Thomas Tu, Chief Medical Officer, each entered into an agreement to permit us to sell shares of our common stock sufficient to satisfy such taxes. We previously determined that we would not carry out the instruction with respect to Mr. Hoffman after he informed us that he will wire sufficient funds to us in advance of the remaining November 15, 2023 distribution so that we can remit such taxes on his behalf to the relevant taxing authorities. As such, we do not intend to sell shares to cover Mr. Hoffman's tax obligations. With respect to Mr. Hykes and Dr. Tu, we intend to sell the required shares, approximately 37,000 and 25,000 respectively, to cover the applicable tax obligations for the November 2023 distribution in accordance with the terms of their previous instructions.

No officer (as defined in Rule 16a-1(f) under the Exchange Act) or director has entered into, modified or terminated a trading plan pursuant to Rule 10b5-1(c) under the Exchange Act, or any other non-rule 10b5-1 trading plan during the three months ended September 30, 2023. None.

Item 6. EXHIBITS

			Incorporated by reference		
Exhibit Number	**Description**	**Form**	**File Number**	**Exhibit**	**Filing Date**
3.1	Amended and Restated Certificate of Incorporation	8-K	001-39293	3.1	5/28/2020
3.2	Amended and Restated Bylaws	8-K	001-39293	3.2	5/28/2020
10.1#	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Andrew Hykes	8-K	001-39293	10.1	9/22/2023
10.2#	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Mitchell Hill	8-K	001-39293	10.2	9/22/2023
10.3#	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Thomas T. Tu, MD	8-K	001-39293	10.3	9/22/2023
31.1	Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
31.2	Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
32.1†	Certifications of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				
32.2†	Certifications of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				
101.INS	Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its EBRL tags are embedded within the inline XBRL document.				
101.SCH	Inline XBRL Taxonomy Extension Schema Document				
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page with Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

		Incorporated by reference			
Exhibit Number	Description	Form	File Number	Exhibit	Filing Date
3.1	Amended and Restated Certificate of Incorporation	8-K	001-39293	3.1	5/28/2020
3.2	Amended and Restated Bylaws	8-K	001-39293	3.2	5/28/2020
31.1	Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
31.2	Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
32.1†	Certifications of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				
32.2†	Certifications of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				
101.INS	Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its EBRL tags are embedded within the inline XBRL document.				
101.SCH	Inline XBRL Taxonomy Extension Schema Document				
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				
104	Cover Page with Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).				

# Indicates management contract or compensatory plan.

† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the U.S. Securities and Exchange Commission and are not to be incorporated by reference into any filing of Inari Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Inari Medical, Inc.
Date: November 1, 2023 April 30, 2024	By:	/s/ Andrew Hykes
		Andrew Hykes
		Chief Executive Officer and President
		(Principal Executive Officer)
Date: November 1, 2023 April 30, 2024	By:	/s/ Mitchell Hill
		Mitchell Hill
		Chief Financial Officer
		(Principal Financial Officer and
		Principal Accounting Officer)

34 35

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew Hykes, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Inari Medical, Inc. (the "registrant");

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d) Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 1, 2023 April 30, 2024

By: /s/ Andrew Hykes

Andrew Hykes

Chief Executive Officer and President
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mitchell Hill, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Inari Medical, Inc. (the "registrant");

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d) Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 1, 2023 April 30, 2024

By: /s/ Mitchell Hill

Mitchell Hill

Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Inari Medical, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 1, 2023 April 30, 2024 | By: /s/ Andrew Hykes

Andrew Hykes
Chief Executive Officer and President
(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Inari Medical, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 1, 2023 April 30, 2024 | By: /s/ Mitchell Hill

Mitchell Hill
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

DISCLAIMER